- In a review of 23,458 patients exposed to adalimumab, the incidence rate of serious demyelinating disorders was ≤0.1 events per 100 person-years (Hamdan et al., 2024)
-The most frequently implicated TNF-α inhibitors in demyelinating events are #etanercept, #infliximab & #adalimumab
1
0
1
0